Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) received Thursday September 17, 2026 a positive EU CHMP opinion recommending marketing authorization for FREHEMGO (denecimig), the company's next-generation factor VIIIa-mimetic bispecific antibody, for treatment of hemophilia A (with or without factor VIII inhibitors) in adults and children. Denecimig offers flexible subcutaneous dosing including once-monthly, every-two-week, or weekly administration in a prefilled-pen presentation. Approval would position denecimig as the second bispecific-antibody FVIIIa mimetic in the European hemophilia A market after Roche's Hemlibra (emicizumab, first launched 2018) — potentially the first meaningful bispecific competition Roche has faced in the Hemlibra franchise. Novo Nordisk expects to launch denecimig in the first European countries in Q4 2026, with broader EU rollout beginning early 2027. The CHMP recommendation is based on data from the Phase 3 FRONTIER program including FRONTIER-2 (adults) and FRONTIER-4 (pediatric) trials. Sandoz-mAbxience separately announced Friday a Hemlibra-referenced biosimilar collaboration, adding a second layer of long-term competitive pressure to the Roche franchise.
Weekend previews of the Monday September 21, 2026 Novo Capital Markets Day in London (webcast live from 09:00 BST / 10:00 CET, running to 15:30 BST / 16:30 CET) landed Saturday and Sunday framing CEO Mike Doustdar's most direct commentary to date on the semaglutide-vs-tirzepatide franchise dynamic. In a Reuters interview released Friday September 18, Doustdar characterized the obesity market as not a 'zero-sum game' as patients 'crave optionality,' rejecting the Morgan Stanley Underweight thesis (September 11 downgrade, DKK 250 target) that Wegovy's U.S. share erosion is structural. Doustdar's 'Novo Way' culture framework announced with the September 14 rebrand emphasizes customer focus, competitiveness, clarity, and care. Sell-side previews (TIKR, Bloomberg, Kontra Invest, TradingKey) frame CMD priorities as: managing the 2031 semaglutide loss of exclusivity, U.S. Wegovy pill script trajectory (>5 million total prescriptions as of August), the CagriSema U.S. obesity decision path (late 2026), the ziltivekimab HERMES/ATHENA terminations, the $1.4 billion Orbis Medicines Sept 17 macrocycle deal, and the Sept 16 Anthropic Claude Science R&D collaboration. NVO shares closed Friday at $42.97 (-0.23% weekly).
Novo (formerly Novo Nordisk) and Copenhagen-based Orbis Medicines announced Thursday September 17, 2026 a multi-target drug discovery and licensing collaboration under which Orbis will apply its proprietary nGen macrocyclic-peptide platform — an integration of generative AI, high-throughput synthesis, and multi-parameter optimization for oral bioavailability — to design next-generation oral macrocycles for high-value cardiometabolic disease targets. Orbis is eligible for up to $1.4 billion in upfront and downstream milestone payments plus tiered royalties on future product sales, and Novo will make a separate strategic equity investment in Orbis. Orbis founding CEO Morten Graugaard disclosed the platform's macrocyclic peptides have achieved up to 18% oral bioavailability in preclinical models — a notable improvement for the macrocycle class that has historically struggled with gut absorption. Orbis was founded in January 2025 with a $93 million Series A led by Novo Holdings and Forbion; the Novo pact is the young biotech's first Big Pharma partnership. Neither company disclosed specific targets or lead candidates. The deal deepens Novo's oral-peptide investment strategy following the January 2026 Wegovy pill launch (now surpassing 5 million U.S. prescriptions) and lands the same week the parent company introduced its shorter 'Novo' operating brand.
Novo (formerly Novo Nordisk; NYSE: NVO; Copenhagen: NOVO-B) confirmed the Capital Markets Day will be held Monday September 21, 2026 in London, webcast live starting 09:00 BST / 10:00 CEST. The event is the first Capital Markets Day under CEO Mike Doustdar and the first outing under the rebranded 'Novo' identity introduced Monday September 14 with the tagline 'Lasting health starts now' and 'The Novo Way' culture framework. Sell-side previews (TIKR, Bloomberg, Kontra Invest) frame the event as a critical reset opportunity following the Friday September 11 Morgan Stanley Underweight downgrade (DKK 250 target), Barclays trim to DKK 300, and HSBC target raise to DKK 320 (Hold). Novo shares trade approximately 32% below the January 2026 52-week high of EUR 54.86. Priorities investors want addressed: the semaglutide 2031 loss of exclusivity, U.S. Wegovy pill script momentum (surpassing 5 million total prescriptions by August), CagriSema's late-2026 U.S. obesity decision path, the ziltivekimab HERMES + ATHENA heart-failure terminations, and how Wednesday's Anthropic Claude Science R&D collaboration and Thursday's $1.4 billion Orbis Medicines macrocycle deal fit the reset narrative.